Key result
Type 2 diabetes mellitus was associated with significantly elevated plasma VEGF levels (526.8 pg/ml vs 317.9 pg/ml) and mean platelet volume (12.5 fl vs 11.4 fl) compared to healthy controls.
Why the study?
Platelet activation and VEGF play roles in diabetic endothelial dysfunction, leading the authors to investigate the association between plasma VEGF levels and MPV.
Are elevated plasma VEGF levels and mean platelet volume (MPV) associated with type 2 diabetes mellitus?
Case-Control (n=130)
Are elevated plasma VEGF levels and mean platelet volume (MPV) associated with type 2 diabetes mellitus?
Absolute Event Rate: 526.8% vs 317.9%
p-value: p=<0.001
Elevated VEGF and MPV levels are significantly associated with T2DM, suggesting their potential utility as biomarkers for evaluating the development and progression of vascular complications.
Increasing evidence in both experimental and clinical studies suggests oxidative stress (OS) plays a major role in the pathogenesis of type 2 diabetes mellitus and its complications. In a physiological condition, appropriate levels of ROS, generated either in restricted amounts or transient fashion, are required to promote physiological angiogenesis and homeostatic maintenance of healthy vasculature. Uncontrolled continuous ROS production will ultimately contribute to pathology and cause tissue damage. One of the most important proangiogenic factors is vascular endothelial growth factor (VEGF) which plays a key role in diabetic endothelial dysfunction, which ultimately leads to pathogenesis of vascular complications. As VEGF is released by activated platelets, hence platelet activation could be the source of VEGF in plasma samples. Increased platelet activity is emphasized to play a role in the development of vascular complications in T2DM patients and platelet volume, a marker of the platelet function and activation, is measured as mean platelet volume (MPV). Therefore, we aimed to investigate the association between plasma VEGF levels and MPV levels that may lead to vascular complications. A case-control study of one hundred patients with T2DM (n = 100) and thirty control subjects (n = 30) were screened from different areas of West Bengal. All procedures were done with the informed consent of participants. Elevated VEGF level was found in T2DM patients (526.8 ± 34.3 pg/ml) compared to healthy controls (317.9 ± 12.9 pg/ml) which was statistically significant. T2DM patients had higher MPV (12.5 ± 0.2 fl) compared to controls (11.4 ± 0.2 fl). Thus the present study showed a significant association between VEGF level in plasma and MPV indicating the severity of vascular complications. Hence, in conclusion, it suggested that VEGF levels along with MPV are a reliable biomarker for evaluating the development and progression of vascular complications.
No takes yet. Share an insight, caveat, or question.
Biswas et al. (2019) conducted a case-control in Type 2 Diabetes Mellitus (n=130). Type 2 Diabetes Mellitus vs. Healthy controls was evaluated on Plasma VEGF level (pg/ml) (p=<0.001). Type 2 diabetes mellitus was associated with significantly elevated plasma VEGF levels (526.8 pg/ml vs 317.9 pg/ml) and mean platelet volume (12.5 fl vs 11.4 fl) compared to healthy controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: